Intestinal microbial diversity in patients with pneumonia and normal individuals
The global pandemic of COVID-19 has been over three years, and the role of intestinal microbiota in the occurrence and development of COVID-19 needs to be further clarified. In this study, we collected fecal samples from 17 hospitalized patients with pneumonia and 17 normal individuals in January 2023, during the outbreak of SARS-CoV-2 Omicron variant in China. Using 16S rDNA sequencing for sample microbial diversity analysis to explore changes in intestinal microbiota in pneumonia patients and the correlation with disease. Through the analysis of microbial composition and co-occurrence relationship between microorganisms, we try to find probiotics with adjuvant therapeutic effect on pneumonia, which may be used in clinical treatment in the future.